Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation
Journal of Enzyme Inhibition and Medicinal Chemistry · 2025
DOI: 10.1080/14756366.2025.2563601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2025. Verfasst von Hong Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Proto-Oncogene Proteins, Protein Kinase Inhibitors. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the research project of Huai’an Science and Technology Bureau, Huai’an Health Commission Research General Project, Jiangsu Commission of Health scientific research project.
Abstract (Originalsprache)
Multiple myeloma, a hematological malignancy, shows PLK1 overexpression in cells correlates with poor prognosis, suggesting PLK1 as a potential therapeutic target. In this study, we discovered five peptides (PLs 1-5) targeting the polo box domain (PBD) of PLK1 through an integrated virtual screening strategy. MST assays confirmed that PLs 1-5 had strong binding affinity for PLK1, especially PL-1 (Kd = 3.11 ± 0.05 nM). Meanwhile, the kinase selectivity assay showed that the PL-1 had no significant inhibitory effects on a panel of other kinases. Molecular dynamics simulation further demonstrated the structural stability of PL-1 and PLK1 complex. Notably, PL-1 displayed potent antiproliferative efficacy against U266 multiple myeloma cells (IC50 = 0.09 ± 0.01 µM). PL-1 showed high intracellular uptake capacity. In addition, PL-1 exhibited good biostability in human serum and liver microsomes. Taken together, PL-1 is a potent and highly selective antitumor agent with considerable therapeutic promise for multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
- Department of Hematology, Siyang Hospital of Traditional Chinese Medicine, Su Qian, China.
Förderung
- the research project of Huai’an Science and Technology Bureau
- Huai’an Health Commission Research General Project
- Jiangsu Commission of Health scientific research project
- Xuzhou Medical University Affiliated Hospital Development Fund General Project
Zitieren
APA
Zhou, H., Guan, L., Lin, G., Yang, X., Zhang, X., Si, Y., Zhang, Y., & Chen, J. (2025). Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2025.2563601
Vancouver
Zhou H, Guan L, Lin G, Yang X, Zhang X, Si Y, et al. Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025. doi:10.1080/14756366.2025.2563601
BibTeX
@article{Zhou2025,
author = {Zhou, Hong and Guan, Lixia and Lin, Guoqiang and Yang, Xiaotian and Zhang, Xingxia and Si, Yejun and Zhang, Yanming and Chen, Juan},
title = {Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2025},
doi = {10.1080/14756366.2025.2563601}
}
EUVIMED